MX2020003665A - Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo. - Google Patents

Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo.

Info

Publication number
MX2020003665A
MX2020003665A MX2020003665A MX2020003665A MX2020003665A MX 2020003665 A MX2020003665 A MX 2020003665A MX 2020003665 A MX2020003665 A MX 2020003665A MX 2020003665 A MX2020003665 A MX 2020003665A MX 2020003665 A MX2020003665 A MX 2020003665A
Authority
MX
Mexico
Prior art keywords
transdermal
guanfacine
therapeutic system
additive
transdermal therapeutic
Prior art date
Application number
MX2020003665A
Other languages
English (en)
Inventor
Marco Emgenbroich
Eva - Marie Prinz
Elke Klein
Heike Kluth
Xavier Thomas
Linda Sue Nartker
Original Assignee
Lts Lohmann Therapie Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie Systeme Ag filed Critical Lts Lohmann Therapie Systeme Ag
Publication of MX2020003665A publication Critical patent/MX2020003665A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un sistema terapéutico transdérmico para la administración transdérmica de guanfacina que comprende una estructura de capa que contiene guanfacina, dicha estructura de capa comprende: A) una capa de refuerzo; y B) una capa que contiene guanfacina; en donde el sistema terapéutico transdérmico comprende al menos un polímero y al menos un aditivo.
MX2020003665A 2017-10-11 2018-10-11 Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo. MX2020003665A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762570745P 2017-10-11 2017-10-11
EP17205546 2017-12-05
PCT/EP2018/077792 WO2019072998A1 (en) 2017-10-11 2018-10-11 TRANSDERMAL THERAPEUTIC SYSTEM FOR TRANSDERMAL DELIVERY OF GUANFACIN HAVING AT LEAST ONE ADDITIVE

Publications (1)

Publication Number Publication Date
MX2020003665A true MX2020003665A (es) 2020-10-01

Family

ID=63878660

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003665A MX2020003665A (es) 2017-10-11 2018-10-11 Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende por lo menos un aditivo.

Country Status (11)

Country Link
US (1) US12214088B2 (es)
EP (1) EP3694498A1 (es)
JP (1) JP7445218B2 (es)
KR (1) KR102776309B1 (es)
CN (1) CN111447926B (es)
AU (1) AU2018348802B2 (es)
BR (1) BR112020007011A2 (es)
CA (1) CA3079697A1 (es)
MX (1) MX2020003665A (es)
TW (1) TWI829654B (es)
WO (1) WO2019072998A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3079694A1 (en) 2017-10-11 2019-04-18 Dow Silicones Corporation Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone acrylic hybrid polymer
BR112020007011A2 (pt) 2017-10-11 2020-10-06 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico para a administração transdérmica de guanfacina compreendendo pelo menos um aditivo
BR112020007091A2 (pt) 2017-10-11 2020-09-24 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico para a administração transdérmica de guanfacina compreendendo um polímero de silicone
US20240374544A1 (en) * 2021-08-30 2024-11-14 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the transdermal administration of guanfacine comprising guanfacine and a mono-carboxylic acid
WO2024040897A1 (zh) * 2022-08-24 2024-02-29 新领医药技术(深圳)有限公司 沙利度胺或其类似物透皮贴剂及其制备方法
CN118697719A (zh) * 2024-02-22 2024-09-27 沈阳药科大学 一种胍法辛贴剂及其制备方法与应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4655767A (en) 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
JPS62289514A (ja) * 1986-04-03 1987-12-16 ハ−コン　ラボラトリ−ズ　コ−ポレ−シヨン 薬理活性物質を経皮、経口又は皮下移植により投与する為の製品
US5028431A (en) * 1987-10-29 1991-07-02 Hercon Laboratories Corporation Article for the delivery to animal tissue of a pharmacologically active agent
JPH01265021A (ja) 1987-10-29 1989-10-23 Hercon Lab Corp 薬理学的活性物質を含有する組成物を動物組織に制御放出および供給するための物品
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5762952A (en) * 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
JPH07145048A (ja) * 1993-11-25 1995-06-06 Sekisui Chem Co Ltd 医療用貼付剤
US5843472A (en) 1997-02-28 1998-12-01 Cygnus, Inc. Transdermal drug delivery sytem for the administration of tamsulosin, and related compositions and methods of use
EP1148106B1 (en) * 1998-07-29 2004-11-24 Teijin Limited Pressure-sensitive adhesive composition and moisture-permeable pressure-sensitive adhesive tape, pressure-sensitive adhesive drug composition, and pressure-sensitive adhesive tape preparation each containing the composition
CN100411692C (zh) * 2004-01-13 2008-08-20 北京康倍得医药技术开发有限公司 丙烯酸基粘合剂组合物及其药物组合物和透皮治疗系统
GT200600396A (es) 2005-09-07 2007-04-23 Dispositivos para la aplicacion de medicamentos transdermicos conteniendo o-desmetil venlafaxina (odv) o sus sales
JP2007284370A (ja) 2006-04-14 2007-11-01 Alcare Co Ltd 体表面用貼付材
KR101432698B1 (ko) 2006-06-06 2014-08-22 다우 코닝 코포레이션 실리콘 아크릴레이트 하이브리드 조성물
US8569416B2 (en) 2006-06-06 2013-10-29 Dow Corning Corporation Single phase silicone acrylate formulation
RU2544702C2 (ru) 2009-04-24 2015-03-20 Хенкель Корпорейшн Клеи на основе силикон-акрилового гибридного полимера
JP5711743B2 (ja) 2010-07-29 2015-05-07 久光製薬株式会社 医療用貼付剤
US9080030B2 (en) 2010-09-14 2015-07-14 Lorama Group International Inc. Low VOC and APE free universal paint colourant compositions
EP2584016A1 (en) 2011-10-21 2013-04-24 Dow Corning Corporation Single phase silicone acrylate formulation
JP2013139554A (ja) 2011-11-29 2013-07-18 Dow Corning Corp シリコーンアクリレートハイブリッド組成物及び該組成物の製造方法
US20150342899A1 (en) 2012-12-28 2015-12-03 Noven Pharmaceuticals, Inc. Compositions and methods for transdermal delivery of amphetamine and clonidine
AU2015296807A1 (en) 2014-07-31 2017-03-09 Noven Pharmaceuticals, Inc. Silicone-containing acrylic polymers for transdermal drug delivery compositions
KR102048682B1 (ko) 2015-02-09 2019-11-27 다우 실리콘즈 코포레이션 다중상 실리콘 아크릴 하이브리드 점탄성 조성물 및 이의 제조 방법
EP3349737A4 (en) * 2015-09-14 2019-05-15 Amneal Pharmaceuticals LLC SYSTEM FOR TRANSDERING
BR112020007091A2 (pt) 2017-10-11 2020-09-24 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico para a administração transdérmica de guanfacina compreendendo um polímero de silicone
BR112020007011A2 (pt) 2017-10-11 2020-10-06 Lts Lohmann Therapie-Systeme Ag sistema terapêutico transdérmico para a administração transdérmica de guanfacina compreendendo pelo menos um aditivo
CA3079694A1 (en) 2017-10-11 2019-04-18 Dow Silicones Corporation Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone acrylic hybrid polymer
WO2019175101A1 (en) 2018-03-13 2019-09-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising a silicone acrylic hybrid polymer

Also Published As

Publication number Publication date
AU2018348802A1 (en) 2020-04-16
US12214088B2 (en) 2025-02-04
CN111447926A (zh) 2020-07-24
KR102776309B1 (ko) 2025-03-07
EP3694498A1 (en) 2020-08-19
WO2019072998A1 (en) 2019-04-18
BR112020007011A2 (pt) 2020-10-06
CA3079697A1 (en) 2019-04-18
RU2020115562A (ru) 2021-11-15
TWI829654B (zh) 2024-01-21
JP7445218B2 (ja) 2024-03-07
US20200397715A1 (en) 2020-12-24
TW201927295A (zh) 2019-07-16
CN111447926B (zh) 2024-04-30
AU2018348802B2 (en) 2024-08-08
JP2020536882A (ja) 2020-12-17
RU2020115562A3 (es) 2022-02-10
KR20200070306A (ko) 2020-06-17

Similar Documents

Publication Publication Date Title
MX2020003667A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero de silicona.
CR20150647A (es) Sistema de liberación transdérmica
MX2020003662A (es) Sistema terapeutico transdermico para la administracion transdermica de guanfacina que comprende un polimero hibrido acrilico de silicona.
BR112016012615A8 (pt) sistemas, e kit
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
CR20140321A (es) Sistema de administracion transdermica que contiene buprenofina
ECSP19021223A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CL2015003314A1 (es) Inhibidores de acc y usos de los mismos
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
MX2017017172A (es) Conjugados de ligador-principio activo (adcs) y conjugados de ligador-profarmaco (apdcs) con grupos enzimaticamente escindibles.
MX2015011466A (es) Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
MX393610B (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres
MX2017016253A (es) Anticuerpos para cd40.
NI201600071A (es) Compuestos de inhibidor de autotaxina
MX2016005017A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
MX2015012576A (es) Composiciones a base de nanoparticulas.
CO2017005500A2 (es) Método para la producción de un sistema de administración farmacéutica
ECSP17044282A (es) Formulación de relación fija de insulina glargina/lixisenatida
BR112017005361A2 (pt) emplastro de opipramol
MX2019007389A (es) Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno.
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств